Shares of YM Biosciences (YMI +16.1%) fall back to earth a bit after surging over 20% in AH and...


Shares of YM Biosciences (YMI +16.1%) fall back to earth a bit after surging over 20% in AH and premarket trading on positive results on testing of its CYT387 drug. Rodman & Renshaw's Reni Benjamin says the big takeaway from the data is that it meets the threshold of attracting interest from other companies looking to partner.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs